The launch of 750mcg teriparatide injection in Australia has involved significant sales . Currently, it’s primarily offered for patients with severe osteoporosis that other therapies have not been effective. Securing this stronger formulation presents as challenging due to specialist approval requirements and limited clinic supply . Despite certa